71 results on '"Sezary Syndrome"'
Search Results
2. Quantification of the median fluorescence intensity of CD3 and CD4 in mycosis fungoides/Sezary syndrome versus non-neoplastic control cases in peripheral blood
3. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
4. Chemical exposures and demographic associations in cutaneous T-cell lymphoma: a large single institution physician validated cohort study
5. Dupilumab-associated mycosis fungoides: a cross-sectional study
6. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications
7. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
8. Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study
9. Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient
10. Radiotherapie kutaner Lymphome
11. Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sézary syndrome
12. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
13. The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas
14. Update zur Extrakorporalen Photopherese
15. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
16. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases
17. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998–2016
18. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units
19. Kutane Lymphome: Klinik – Diagnostik – Therapie
20. Kutane Lymphome: Klinik – Diagnostik – Therapie
21. Kutane Lymphome: Klinik – Diagnostik – Therapie
22. Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas
23. Oral Mycosis Fungoides: A Report of Three Cases and Review of the Literature
24. Primär kutane Lymphome – eine Fallserie von 163 Patienten
25. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy
26. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome
27. Large Cell Transformation of Oral Mycosis Fungoides
28. What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments
29. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome
30. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)
31. Diagnostik kutaner Lymphome
32. Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach
33. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome
34. Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover
35. CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214
36. Sézary Syndrome: Clinical and Biological Aspects
37. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome
38. An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case–control study
39. Mature T-cell leukemias: Molecular and Clinical Aspects
40. Analysis of the IL-31 pathway in Mycosis fungoides and Sézary syndrome
41. Progressive neurolymphomatosis with cutaneous disease: Response in a patient with mycosis fungoides
42. Update on Epidemiology of Cutaneous T-Cell Lymphoma
43. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome
44. Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1
45. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome
46. Corneal perforation due to limbal involvement in Sézary syndrome
47. Interleukin-16 as a Marker of Sézary Syndrome Onset and Stage
48. Structuration d’un réseau national et d’une réunion de concertation pluridisciplinaire nationale de recours pour la prise en charge des lymphomes cutanés rares
49. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma
50. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.